Navigation Links
Penicillin redux: Rearming proven warriors for the 21st century
Date:4/14/2014

Penicillin, one of the scientific marvels of the 20th century, is currently losing a lot of battles it once won against bacterial infections. But scientists at the University of South Carolina have just reported a new approach to restoring its combat effectiveness, even against so-called "superbugs."

Bacteria have been chipping away at the power of the penicillin family of drugs since their first wide-scale use as antibiotics in the 1940s. For example, the staph infection, brought about by the bacterium Staphylococcus aureus, was once readily treated with penicillin and its molecular cousins.

But that bug has changed. In the 1960s, a new strain arrived, termed MRSA for methicillin- (or sometimes multidrug-) resistant S. aureus. It has become a serious public health problem because the earliest deployed antibiotics are often useless against the new strain, and its prevalence has only increased since it was first observed. MRSA (pronounced mer-suh) is sometimes called a superbug because of the difficulty physicians have in treating infected patients.

The S. aureus microbe has evolved the MRSA strain by developing a variety of defenses against antibiotics to which they've been exposed. One of those defenses effectively neutralizes penicillin's greatest strength.

That strength is its molecular core, a cyclic four-membered amide ring termed a beta-lactam. It is a common structural element of the penicillins, their synthetic and semi-synthetic derivatives, and other related molecules that constitute the broad family of drugs called the beta-lactam antibiotics. Just a few examples (of dozens) include amoxicillin, ampicillin and cefazolin.

The beta-lactam structure in a molecule is something that many bacteria don't like at all. It greatly hinders their ability to reproduce by cell division, and so chemists have for years spent time making molecules that all contain the beta-lactam structural motif, but differ in the surrounding molecular "shrubbery." Physicians heavily use the many versions of beta-lactam antibiotics to fight bacterial infections, and many have been retired because they're no longer effective against the defenses bacteria have evolved in response.

One of the most effective bacterial defenses is an enzyme called beta-lactamase, which chews up the beta-lactam structure. Some bacteria, such as MRSA, have developed the ability to biosynthesize and release beta-lactamase when needed. It's a devastating defense because it's so general, targeting the common structural motif in all of the many beta-lactam antibiotics.

But that also creates the opportunity for a general approach to solving the problem, which is what Carolina's Chuanbing Tang and colleagues just reported in the Journal of the American Chemical Society.

"Instead of developing new antibiotics, here we ask the question, 'can we recycle the old antibiotics?' " he said. "With traditional antibiotics like penicillin G, amoxicillin, ampicillin and so on, can we give them new life?"

The approach pairs the drug with a protective polymer developed in Tang's chemistry laboratory. In lab tests, graduate student Jiuyang Zhang prepared a cobaltocenium metallopolymer that greatly slowed the destructiveness of beta-lactamase on a model beta-lactam molecule (nitrocefin).

The interdisciplinary team, which included Mitzi Nagarkatti and Alan Decho, from the university's School of Medicine and Arnold School of Public Health, respectively, also showed that the antimicrobial effectiveness of the four beta-lactams studied in detail was enhanced by the polymer. The enhancement was modest against two strains, but very pronounced with the hospital-associated strain of MRSA (HA-MRSA).

The metallopolymer by itself even demonstrated antimicrobial properties, lysing bacterial cells while leaving human red blood cells unaffected. By a variety of measures, the polymer was found to be nontoxic to human cells in laboratory tests.

The project is still far from clinical use, but Tang knows moving forward is imperative.

"In the United States every year, around 100,000 patients die of bacteria-induced infections," Tang said. "And the problem is increasing because bacteria are building resistance.

"It's a really, really big problem, not only for individual patients, but also for society."


'/>"/>

Contact: Steven Powell
803-777-1923
University of South Carolina
Source:Eurekalert  

Related medicine news :

1. Penicillin equally effective as big gun antibiotics for treating less severe childhood pneumonia
2. Penicillin Prevents Return of Leg Infection Called Cellulitis: Study
3. Economic analysis finds penicillin, not "the pill," may have launched the sexual revolution
4. CONRAD wins USAID Science and Technology Pioneers Prize for development of first vaginal gel proven to reduce HIV
5. Study examines repeat colonoscopy in patients with polyps referred for surgery without biopsy-proven cancer
6. Discover 50 Yoga Exercises That Are Proven Good For Health – V-kool
7. VitaPro Labs Launches New Withdrawal Aid System at WithdrawalAid.com, a Supplement Proven To Ease Opioid Withdrawal Symptoms
8. Added benefit of saxagliptin as monotherapy is not proven
9. Phen375: The Clinically Proven Highly Effective Weight Loss Pills Now Available in the Market with 1 Month Extra Supply for Limited Time
10. Har Vokse: The Clinically Proven Highly Effective Hair Regrowth Treatment Product Now Offers 1 Month Extra Supply for Limited Time!
11. Revitol Eye Cream: The Clinically Proven Highly Effective Cream for Eye Dark Circles, Puffiness, Fine Lines and Wrinkles; Now Available with 1 Extra Jar Offer!
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Penicillin redux: Rearming proven warriors for the 21st century
(Date:7/27/2017)... ... July 27, 2017 , ... MAP Health ... this year’s Fierce Innovation Awards: Healthcare Edition 2017, an awards program from the ... of Population Health Management/Patient Engagement Solutions. , MAP was selected as a ...
(Date:7/27/2017)... , ... July 27, 2017 , ... Cremations recently surpassed ... Funeral Directors Association, this trend is expected to continue with over 70% of Americans ... a growing demand for new innovations that enable families to celebrate the life of ...
(Date:7/26/2017)... Miami, FL (PRWEB) , ... July 26, 2017 , ... ... caps that treat hereditary hair loss. The new Flexible Fitting Design offers a more ... of Capillus, LLC is delighted with the improvements to the home-use laser therapy caps ...
(Date:7/26/2017)... Madison, WI (PRWEB) , ... July 26, 2017 ... ... launch of Talent Management Solutions as part of their continued efforts to provide ... retain, and develop the best IT resources and build dynamic, high-performing teams to ...
(Date:7/26/2017)... PA (PRWEB) , ... July 26, 2017 , ... “We ... said Dr. Ahmed Mauassra, from San Jose, Calif., “so we invented the MAGNETIC/ LOCK ... the bracket portion of orthodontic braces. In doing so, it offers an effective alternative ...
Breaking Medicine News(10 mins):
(Date:7/24/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO ... quarter 2017 operating results on Monday, August 7, 2017 ... at 5:00 p.m. ET. ... live broadcast of the conference call by dialing 877-201-0168 ... 51641230 approximately 15 minutes prior to the call. A ...
(Date:7/21/2017)... 21, 2017 Did you know that PhRMA member companies ... that combined spending on brand medicines, generics and the supply chain ... accounting for just half of this (7 percent)? Or that ... the world,s venture capital investments in high-growth biopharmaceutical startups? ... ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology: